Finivi Inc. Sells 24,340 Shares of Tempus AI, Inc. $TEM

Key Points

• Finivi Inc. cut its Tempus AI position by 69.5% in the second quarter, selling 24,340 shares and retaining 10,684 shares valued at approximately $619,000. Institutional investors collectively own 24.22% of the company.
• Analysts have a consensus “Hold” rating on Tempus AI, with an average price target of $64.92; coverage includes nine Buy, six Hold and two Sell ratings.
• Tempus AI reported better-than-expected quarterly results, with an adjusted loss of $0.04 per share and revenue of $382.49 million, up 21.6% year over year. However, insiders sold 723,981 shares worth about $34.9 million over the past 90 days.

Finivi Inc. decreased its position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 69.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,684 shares of the company's stock after selling 24,340 shares during the period. Finivi Inc.'s holdings in Tempus AI were worth $619,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the third quarter valued at $26,000. Los Angeles Capital Management LLC purchased a new position in shares of Tempus AI during the 4th quarter valued at $27,000. Harvest Fund Management Co. Ltd bought a new position in shares of Tempus AI during the 3rd quarter worth $38,000. Whittier Trust Co. increased its holdings in Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company's stock worth $41,000 after acquiring an additional 570 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Tempus AI by 88.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company's stock worth $44,000 after acquiring an additional 325 shares during the last quarter. 24.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Piper Sandler lowered their price objective on Tempus AI from $58.00 to $56.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 4th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Tempus AI in a research note on Wednesday, June 17th. Wall Street Zen raised shares of Tempus AI from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. Freedom Capital upgraded shares of Tempus AI to a "hold" rating in a research note on Tuesday, June 30th. Finally, Wolfe Research began coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a "peer perform" rating on the stock. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $64.92.

Insider Activity at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 250,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total value of $10,515,000.00. Following the sale, the chief executive officer directly owned 200,000 shares in the company, valued at $8,412,000. This represents a 55.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 11,529 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the transaction, the chief financial officer directly owned 114,866 shares of the company's stock, valued at approximately $6,317,630. The trade was a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 723,981 shares of company stock valued at $34,879,442. Corporate insiders own 24.26% of the company's stock.

Tempus AI Stock Performance

Shares of TEM opened at $52.05 on Monday. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The stock's 50-day simple moving average is $51.33 and its 200 day simple moving average is $51.83. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The stock has a market capitalization of $9.39 billion, a price-to-earnings ratio of -36.15 and a beta of 3.58.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the previous year, the firm earned ($0.22) EPS. The company's quarterly revenue was up 21.6% compared to the same quarter last year. Research analysts forecast that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source